The pharmaceutical company Rovi obtained a net profit of 199.7 million euros in 2022, a figure 30% higher than that of 2021, as reported on Tuesday to the National Securities Market Commission (CNMV).
The company's operating income increased by 26% in 2022, to 817.7 million euros, thanks to the "strength" of the manufacturing business for third parties, which grew 52% in sales, and the pharmaceutical specialty business, whose sales increased by 8%. In 2022, it exceeded the high band of its forecasts for growth in operating income (15%-20%) by registering an increase of 26%.
In any case, by 2023 it expects its operating income to decrease between 10% and 20%, although it will exceed the figure reached in 2021 by between 5% and 10%. covid for Moderna assumes a new post-pandemic scenario in which covid would "predictably" be a seasonal disease and the vaccine would, in principle, be administered once a year. For this reason, it foresees a "stronger" second semester than the first in terms of the manufacturing business for third parties.
"Taking into account the aforementioned forecast of a reduction in operating income in 2023 and that Rovi will continue with its investment policy, it is reasonable to expect that the company's results can also be adjusted downwards in 2023," he concludes.
For now, Rovi will propose to its general shareholders' meeting the distribution of a dividend charged to 2022 and the results of previous years in the amount of 1.2938 euros per share. It represents an increase of 35% with respect to the dividend paid from the results of 2021.
